4.5 Article

Screening of Inhibitors Targeting Heat Shock Protein 47 Involved in the Development of Idiopathic Pulmonary Fibrosis

Journal

CHEMMEDCHEM
Volume 16, Issue 16, Pages 2515-2523

Publisher

WILEY-V C H VERLAG GMBH
DOI: 10.1002/cmdc.202100064

Keywords

heat shock protein 47 inhibitors; fibril formation assay; idiopathic pulmonary fibrosis; natural products; drug discovery

Funding

  1. Japanese Society for the Promotion of Science (JSPS KAKENHI) [20K08520]
  2. Platform Project for Supporting Drug Discovery and Life Science Research (Basis for Supporting Innovative Drug Discovery and Life Science Research (BINDS)) from AMED [JP20am0101088, 2262]
  3. Grants-in-Aid for Scientific Research [20K08520] Funding Source: KAKEN

Ask authors/readers for more resources

The study prepared human HSP47 and established an inhibitor screening system. Among the compounds screened, three were found to effectively inhibit the function of HSP47, with epigallocatechin-3-O-gallate from tea leaves being one of them.
Heat shock protein 47 (HSP47), a collagen-specific molecular chaperone, is causally related to fibrotic diseases, including idiopathic pulmonary fibrosis. The identification of Compounds that interfere with the HSP47-collagen interaction is essential for the development of relevant therapeutics. Herein, we prepared human HSP47 as a soluble fusion protein expressed in E. coli and established an assay system for HSP47 inhibitor screening. We screened a natural and synthetic Compound library established at Nagasaki University. Among 1023 Compounds, 13 exhibited inhibitory activity against human HSP47, of which three inhibited its function in a dose-dependent manner. Epigallocatechin-3-O-gallate, one of these three Compounds, is a typical polyphenol Compound derived from tea leaves. Structurally related Compounds were synthesized and examined for their activity, revealing a hydroxyl group at A-ring position 5 as important for its activity. The present findings provide valuable insight for the development of natural product-derived therapeutics for fibrotic diseases, including idiopathic pulmonary fibrosis.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available